JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B
Synopsis
Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale.
Johnson & Johnson (JNJ) shares jumped 1% on Thursday following reports that the company is eyeing a potential sale of its orthopedics segment.
Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale. The drugmaker has been planning to separate the unit.
JNJ is expected to meet possible buyers in the coming weeks with documents and financials it is putting together, the report added.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.